In this study, we describe an interaction between cryptochromes and the glucocorticoid receptor, through which Cry1 and Cry2 repress glucocorticoid-receptor-dependent transcription, including the ...

Thus, the glucocorticoid receptor is a double-edged sword in prostate cancer. Due to it promoting the development of drug resistance in prostate cancer, it was shown to have oncogenic effects.

In prostate cancer, the glucocorticoid receptor can replace the activity of the androgen receptor, which is main oncogenic factor in this cancer, when its activity is inhibited by drug therapy.